Your browser doesn't support javascript.
Successful use of Impella 5.5 to manage cardiogenic shock complicated by COVID-19.
Mahrokhian, Shant H; Nordan, Taylor; Ortoleva, Jamel P; Cobey, Frederick C; Chen, Frederick Y; Kapur, Navin K; Kawabori, Masashi.
  • Mahrokhian SH; Division of Cardiac Surgery, CardioVascular Center, Tufts Medical Center, Boston, Massachusetts, USA.
  • Nordan T; Division of Cardiac Surgery, CardioVascular Center, Tufts Medical Center, Boston, Massachusetts, USA.
  • Ortoleva JP; Division of Anesthesiology and Perioperative Medicine, Division of Cardiac Surgery, CardioVascular Center, Tufts Medical Center, Boston, Massachusetts, USA.
  • Cobey FC; Division of Anesthesiology and Perioperative Medicine, Division of Cardiac Surgery, CardioVascular Center, Tufts Medical Center, Boston, Massachusetts, USA.
  • Chen FY; Division of Cardiac Surgery, CardioVascular Center, Tufts Medical Center, Boston, Massachusetts, USA.
  • Kapur NK; Division of Cardiology, CardioVascular Center, Tufts Medical Center, Boston, Massachusetts, USA.
  • Kawabori M; Division of Cardiac Surgery, CardioVascular Center, Tufts Medical Center, Boston, Massachusetts, USA.
J Card Surg ; 36(12): 4783-4785, 2021 Dec.
Article in English | MEDLINE | ID: covidwho-1443298
ABSTRACT

BACKGROUND:

Acute decompensated heart failure in patients with coronavirus disease 2019 (COVID-19) is becoming increasingly common.

AIMS:

In this case report, we describe the successful use of an Impella 5.5 (Abiomed) to treat cardiogenic shock refractory to inotropic therapy. MATERIALS &

METHODS:

Transthoracic and transesophageal echocardiography confirmed severely diminished left ventricular ejection fraction and a reverse-transcription polymerase chain reaction test revealed that the patient was COVID-19 positive during his hospital admission.

RESULTS:

Following initiation of inotropic therapy, we placed an Impella 5.5 for further cardiac support. The patient's LVEF and cardiac index improved after 21 days on the Impella 5.5 and was maintained following explant. DISCUSSION &

CONCLUSION:

The findings reported here demonstrate successful use of an Impella 5.5 to improve native heart function in refractory cardiogenic shock and further indicate its use as an option for those in acute decompensated heart failure who have tested positive for COVID-19 infection.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Heart-Assist Devices / COVID-19 Type of study: Case report / Observational study / Prognostic study Limits: Humans Language: English Journal: J Card Surg Journal subject: Cardiology Year: 2021 Document Type: Article Affiliation country: Jocs.16038

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Heart-Assist Devices / COVID-19 Type of study: Case report / Observational study / Prognostic study Limits: Humans Language: English Journal: J Card Surg Journal subject: Cardiology Year: 2021 Document Type: Article Affiliation country: Jocs.16038